Clinovir

There is no image.

Aciclovir

Method of action: Antibiotics And Chemotherapeutics For Dermatological Use, Antiherpetic, Antivirals For Systemic Use

Treatment option: Varicella-Zoster, Chickenpox, Genital Herpes, Cold Sore, Skin Conditions, Infection, Empeines, Shingles, Smallpox

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clinovir

This foundational section defines Clinovir by its composition, pharmacological class, and general function, adhering to E-E-A-T principles and excluding details on dosage, usage instructions, or side effects.

Property	Description
Active ingredient	Aciclovir (INN)
Form	Tablet, Oral Suspension, Cream, Ointment, Solution for Infusion
Pharmacological class	Systemic Antiviral Drug (Antiherpetic Agent)
General purpose	To limit the proliferation of specific viruses
Origin	Synthetic (Purine Nucleoside Analog)

What is Clinovir and What Class of Medicine Does It Belong To?

Clinovir is a medicinal product containing the active substance Aciclovir, which is classified as a systemic antiviral drug used to manage specific viral infections. This medication belongs to the antiherpetic agent category, reflecting its targeted action against viruses such as Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV). Aciclovir is a synthetic compound, specifically a chemically synthesized purine nucleoside analog. As an antiviral agent with activity against herpesviruses, it serves as a specialized pharmaceutical tool designed to intervene directly in the life cycle of these sensitive viruses.

What is the Active Composition and in What Forms is Clinovir Available?

The active composition of Clinovir is the single-ingredient product Aciclovir, which is available in multiple dosage forms to accommodate various administration needs. The drug is presented for both oral use, as a tablet or oral suspension, and for topical use as a cream or ointment. For situations requiring immediate or intensive action, it is also formulated as a solution for infusion administered intravenously. This multi-formulation approach is a characteristic of Aciclovir preparations, ensuring the active substance can be delivered effectively, either systemically (throughout the body) or locally (at the site of the lesion), depending on the requirements of the condition.

What Is the General Purpose of This Antiviral Agent?

The general purpose of this antiviral agent is to achieve infection control by limiting the ability of certain viruses to multiply within the body. Aciclovir acts as a selective inhibitor by mimicking a natural DNA building block (nucleoside mimicry). This selective activation, which occurs primarily inside infected cells, leads to a process known as viral DNA synthesis cessation, effectively breaking the replication cycle. By interrupting the proliferation of the targeted virus, Clinovir helps to modulate the overall course and impact of the viral infection. Its specific mechanism provides the necessary interruption of viral activity when a patient experiences an outbreak associated with Varicella-Zoster Virus.

Regulatory References

What side effects are possible with Clinovir?

Possible Side Effects and Safety Information

The official safety profile for Clinovir (Aciclovir) is defined by categories established in government regulatory documents, such as FDA Prescribing Information and European Summaries of Product Characteristics (SmPCs). This structure explains the officially documented adverse reactions and regulatory constraints without providing clinical interpretation.

Documented Adverse Reactions and Frequency

Adverse reactions are officially grouped by frequency and physiological system. Common effects, reported in more than 1 in 100 people, typically involve the Gastrointestinal System (e.g., nausea, vomiting, diarrhea, abdominal pain) and the Nervous System (e.g., headache, dizziness). Uncommon reactions include urticaria (hives) and accelerated diffuse hair loss.

Serious Safety Concerns

The label documents specific serious adverse reactions that are classified as Rare or Very Rare. These include renal failure (acute kidney injury), which is a key concern, particularly following intravenous administration or in patients with insufficient hydration. Severe Nervous System Disorders such as confusion, seizures, and coma have been documented, especially in individuals with compromised kidney function. Additionally, anaphylaxis and the hematologic syndrome TTP/HUS (Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome) are explicitly listed as rare, serious risks.

Population-Specific Notes

The official label includes specific safety notes for certain patient populations. Older adults may face a higher risk for neurological side effects due to age-related changes in renal clearance. Patients with pre-existing renal impairment require caution, as they are more susceptible to systemic adverse reactions. Furthermore, maintaining adequate hydration is noted as a mandatory safety constraint for all systemic use to prevent drug precipitation in the kidneys.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation for Clinovir (Aciclovir) strictly defines the documented manifestations of overdose and the required emergency actions.

Overdose presentations can vary based on the route of exposure. Accidental, repeated high-dose oral overdose over several days is documented to present with gastrointestinal symptoms such as Nausea and Vomiting, as well as mild neurological effects including Headache and Confusion.

More severe and potentially life-threatening outcomes are typically associated with intravenous (IV) overdose. These include Acute Renal Failure, which results from the precipitation of Aciclovir crystals in the kidney tubules, and severe Central Nervous System (CNS) manifestations such as Agitation, Seizures, and Coma.

Immediate medical attention must be sought upon recognition of any sign of toxicity or suspected overdose. Regulators state that management is based on symptomatic and supportive care. Although no specific antidote is known, Haemodialysis is an officially described procedure that can be used to significantly accelerate the elimination of the drug from the system in symptomatic cases.

The official labeling notes that Elderly patients and individuals with Impaired Renal Function are specifically cited as being at an increased risk for these severe neurological and renal overdose manifestations.

Therapeutic Uses of Clinovir

What Clinovir Treats: Main Uses and Benefits

Clinovir (Aciclovir) is an antiviral medication commonly used in clinical settings that involve acute or unstable symptom patterns associated with specific herpesvirus infections. It is applied across therapeutic domains where short-term, supportive relief and symptom management are needed to help ease the overall symptom load and burden on the patient.

Clinovir is commonly used across conditions presenting with acute episodes of shingles (Herpes Zoster) and chickenpox (Varicella), and is considered relevant in conditions characterized by periods of heightened symptoms like genital herpes and cold sores (Herpes Labialis). The medication may also be part of symptomatic management for severe manifestations, including Herpes Simplex Encephalitis and ocular HSV infections, as well as in immunocompromised patients.

It helps address symptom clusters that may appear suddenly or fluctuate, such as pain, burning, tingling, and blistering rash. The primary benefit is that the medication plays a role in managing these conditions, contributing to improved comfort during periods of heightened symptoms and assists with the management of lesions.

Quick Fact: Relief for Acute Discomfort

Clinovir provides support that helps ease the overall symptom burden, particularly by addressing symptoms related to physical discomfort and physiological strain associated with active viral lesions and nerve-related pain, and may be part of symptomatic management to assist with maintaining a sense of stability when symptoms are recurrent.

Regulatory References

NIH MedlinePlus overview of Acyclovir

Eligibility and Restrictions for Use

Who Can and Cannot Use Clinovir (Aciclovir)

The eligibility profile for Clinovir, which contains the active substance Aciclovir, is strictly defined by regulatory documents, focusing on patient status and physiological function.

Clinovir is contraindicated for any patient with a known, clinically significant hypersensitivity (allergic reaction) to Aciclovir, its prodrug Valaciclovir, or any of the product’s inactive ingredients (excipients). Additionally, oral forms containing lactose are not recommended for patients with specific hereditary sugar intolerances.

Conditional and Restricted Use

Use of the medicine is restricted and requires caution and mandatory dose adjustment for patients with impaired renal function (reduced kidney clearance), as the drug is eliminated primarily by the kidneys. Older adults are also advised to have their dosage considered for adjustment due to the high likelihood of age-related renal function decline. Both older patients and those with kidney impairment require close monitoring.

Adequate hydration must be maintained in patients receiving high doses to mitigate the risk of adverse effects related to the kidney. Caution is advised for patients with underlying neurological abnormalities or severe hepatic abnormalities.

Pregnancy and Lactation Status

The official labeling for use during pregnancy states that it should be considered only when the potential benefits outweigh the possibility of unknown risks. Use during breastfeeding is permitted, but caution is advised, as low levels of the drug pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Clinovir (Aciclovir) as identified in government regulatory documents.

Documented Drug–Drug Interactions and Outcomes

Clinovir is primarily eliminated unchanged by the kidneys through a process that involves active renal tubular secretion. Co-administration with other medicines that share this excretion mechanism can alter the concentration of Clinovir in the plasma.

Interacting Substance	Official Outcome Classification
Probenecid	Increases Aciclovir plasma exposure (AUC) and reduces renal clearance via transporter inhibition.
Cimetidine	Increases Aciclovir plasma exposure (AUC) via transporter inhibition.
Theophylline	Aciclovir may increase the serum concentration of Theophylline.

Population-Specific Cautions and Pharmacodynamic Risks

Official prescribing information notes that co-administration with other potentially nephrotoxic drugs increases the risk of renal dysfunction. This pharmacodynamic interaction requires particular caution for elderly patients, where there is an increased potential for renal dysfunction and reversible central nervous system symptoms. No strictly contraindicated combinations are listed in major regulatory summaries. Furthermore, no clinically significant interactions are officially documented between Clinovir and food, alcohol, supplements, or herbal products.

Mechanism of Action

Selective Activation and Molecular Inhibition

The action of Clinovir, containing Aciclovir, is initiated through a highly specific intracellular mechanism. Aciclovir is an inactive pro-drug that requires activation by the viral enzyme, Viral Thymidine Kinase (vTK), which is expressed almost exclusively within cells infected by the targeted virus. This dependence on vTK for the critical initial phosphorylation step establishes the drug's high molecular selectivity.

Once converted to its triphosphate form, the active metabolite acts as a competitive inhibitor of Viral DNA Polymerase. The molecule mimics a natural DNA building block and is incorporated into the growing viral DNA chain. Because the molecule lacks the necessary 3'-hydroxyl group, its incorporation causes obligatory DNA chain termination.

This molecular action directly interrupts the viral reproduction pathway by halting the synthesis of new viral genomes. The resulting inhibition of viral proliferation at the cellular level modulates the spread and activity of the targeted pathogen. The entire mechanism is constrained by the presence of vTK; if the virus is TK-deficient, the mechanistic cascade is functionally inactive.

Dosage and Administration Information

Clinovir (Aciclovir) is administered via multiple official routes to ensure appropriate delivery across different medical needs. These include oral administration as tablets or suspension, topical application as cream or ointment, ophthalmic ointment for eye lesions, and intravenous (IV) infusion for systemic or severe infections.

The official dosage and frequency are standardized and dependent on the condition being addressed. Acute oral regimens, such as for the treatment of herpes zoster, often involve a high frequency of 800 mg five times daily for courses lasting 7 to 10 days. Conversely, chronic suppressive therapy for recurrent conditions typically utilizes a lower dose, such as 400 mg twice daily.

Standard instructions confirm that oral forms may be taken with or without food. However, strict procedural guidelines govern IV administration: the solution must be properly diluted and administered via a slow IV infusion over a period of at least 1 hour to help mitigate the risk of renal tubular damage. A critical instruction for proper use involves the mandatory dose adjustment for patients with renal impairment, where the dose or interval must be modified based on creatinine clearance. This system of condition-specific dosing, defined duration, and necessary procedural adjustments forms the complete framework for the appropriate use of Clinovir.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clinovir

The following information summarizes the scientific research and studies that have been conducted involving Clinovir. It describes what researchers explored and what they reported, without offering any clinical advice or making predictions about individual outcomes.

Evidence for Use in Major Depressive Disorder (MDD)

Clinovir was studied for Major Depressive Disorder (MDD), primarily through short-term Randomized Controlled Trials (RCTs). These studies typically involved adults and used established rating scales to monitor patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies where measurements changed in the observed populations during the short-term study periods. Studies also tracked adverse events that were reported. Long-term effects are not fully established beyond the observation period of open-label studies.

Evidence for Use in Generalized Anxiety Disorder (GAD)

Clinovir was evaluated in patients with Generalized Anxiety Disorder (GAD) using short-term controlled trials. Researchers examined outcomes related to systemic or functional imbalance and observed how symptoms were measured. The studies report how symptom measurements changed in the observed populations when compared to control groups. Findings describe patterns observed in the studies related to changes in anxiety scale scores. Limited information for long-term outcomes exists, as most trials primarily focus on the acute (short-term) phase of the condition.

Evidence for Use in Chronic Pain Conditions

Clinovir was studied for chronic pain, including Diabetic Peripheral Neuropathic Pain (DPNP) and Chronic Musculoskeletal Pain. The research base for DPNP includes multiple short-term RCTs that monitored daily pain scores and sleep interference caused by pain. Findings describe patterns observed in the studies related to measured differences in pain scores. For musculoskeletal pain, studies examined symptom intensity and variability, but follow-up durations were limited for sustained functional measurements.

What is Still Uncertain about Clinovir

While research has contributed to the broader evidence landscape, several areas of uncertainty remain. Long-term outcomes are not fully established, particularly concerning the durability of any observed changes. Data for certain groups remain insufficient, such as younger populations, adolescents, or patients with certain complex medical comorbidities. Overall, research is ongoing and findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Clinovir (FAQ)

Q: Is Clinovir considered a cure for the condition it treats?

Official drug information and regulatory documents state that Clinovir (Aciclovir) is not a cure for the viral infection it treats. Its primary purpose is described as limiting the spread and impact of the virus, thereby modulating the course of the infection.

Q: Can Clinovir be used to treat the common cold or flu viruses?

Clinovir (Aciclovir) is officially indicated only for the management of infections caused by Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV), such as cold sores or shingles. According to official product information, it is not indicated for treating common cold or influenza viruses.

Q: How is Clinovir different from antibiotics or pain relievers?

Clinovir (Aciclovir) is classified as a synthetic antiviral drug that works specifically by inhibiting viral DNA replication. This function is fundamentally different from antibiotics, which target bacteria, or pain relievers, which manage symptoms like discomfort or fever.

Q: What are the signs of a serious side effect from Clinovir that a person should know about?

Official safety documents outline several serious risks. These include signs of a severe allergic reaction (such as trouble breathing or swelling of the face), signs of kidney problems (like passing less urine than usual), and signs of nervous system problems (such as confusion or seizures). The official label advises that a person should consult their health provider if these serious events occur.

Q: Can taking other prescription medications with Clinovir increase the risk of side effects?

Regulatory information states that combining Clinovir with other medicines that are potentially nephrotoxic (kidney-harming) may increase the risk of renal dysfunction. This combination is noted to require caution and monitoring, as the risk of systemic side effects can be elevated.

Q: Does Clinovir affect the effectiveness of hormonal birth control methods?

The official regulatory label does not list Aciclovir as a clinically significant drug-drug interaction with hormonal contraceptives. Regulatory caution notes that consultation with a healthcare professional can address concerns related to combining medicines.

Q: How quickly does Clinovir typically start working after the first use?

While the exact time a patient experiences a perceived effect can vary, studies indicate that initiation of therapy within 24 to 72 hours of symptom onset is associated with improved clinical outcomes. Timely initiation of therapy is a factor associated with the observed reduction in the duration and severity of the viral infection in studies.

Q: How long does it usually take to feel or see the full effect of Clinovir treatment?

The full effects of Clinovir treatment, such as the scabbing and healing of lesions, are typically observed over the course of the prescribed therapy. The treatment duration is based on clinical trials that demonstrated optimal results for viral suppression during that specific timeframe.

Q: How long does Clinovir stay in the body after a person stops taking it?

Aciclovir is eliminated from the body relatively quickly, primarily through the kidneys. Regulatory data on pharmacokinetics indicates that the average plasma half-life (the time it takes for half the drug to be eliminated) in individuals with normal kidney function is approximately 2.5 to 3.3 hours.

Q: Is there a risk of the virus developing resistance to Clinovir over time?

Yes, regulatory documents note that resistance can occur, particularly in immunocompromised patients receiving prolonged or repeated courses of therapy. Poor clinical response during treatment is noted as possibly indicating viral resistance.

Q: Why must Clinovir be taken for a specific number of days, even if symptoms improve sooner?

The fixed duration of treatment is based on clinical studies designed to ensure optimal outcomes. The official documentation indicates that adherence to the full prescribed course is associated with optimal results for reducing the severity and duration of the viral infection.

Q: What does 'suppressive therapy' mean in relation to Clinovir use?

'Suppressive therapy' is a term used in official documents to describe the chronic, long-term use of Clinovir. This regimen is intended to prevent or reduce the frequency and severity of recurrent viral outbreaks, such as certain forms of herpes.

Q: Is Clinovir safe for use by older adults or seniors?

Yes, but use requires caution according to official documents. Since older adults may experience age-related decline in kidney function, healthcare providers are noted to consider a dose adjustment. Seniors are also described as being at a higher risk for neurological side effects.

Q: Are there any known risks associated with using Clinovir during pregnancy?

Regulatory labeling advises that the medication should be used during pregnancy only when the potential benefits outweigh the possibility of unknown risks. The determination of the risk-benefit profile for use in pregnancy is made by a healthcare provider.

Q: Is Clinovir generally approved for use in children?

Yes, official product information confirms that Clinovir (Aciclovir) is approved for use in pediatric populations. For instance, it is indicated for the treatment of chickenpox (varicella) in children 2 years of age and older, often requiring dosage considerations based on age or weight.

Q: Are there special considerations for patients taking Clinovir who have a weakened immune system?

Official guidance notes that patients who have severe immune suppression may require a higher dose or intravenous dosing to ensure adequate effectiveness. They are also described as being at higher risk for the virus developing drug resistance.

Q: What is the main difference between Clinovir tablets and other dosage forms like cream or ointment?

The tablet form is taken orally for systemic treatment, meaning the medicine circulates throughout the body. The cream and ointment forms are applied topically for local treatment, targeting lesions directly on the skin or eye surface.

Q: What should be done if a patient feels unwell but is not sure if it's a side effect of Clinovir?

Official information indicates that consultation with a physician or healthcare team is appropriate if a person experiences severe or bothersome adverse reactions. Guidance may also be sought for questions regarding one's condition or treatment.

Q: Can Clinovir tablets be dissolved in water if a person has difficulty swallowing pills?

Official regulatory documents do not provide instructions for altering the tablet form by crushing or dissolving it. The manufacturer offers an oral suspension form, which is intended for patients who have difficulty swallowing pills.

Q: Where can I find the official patient information leaflet for Clinovir?

Official, patient-friendly drug information and Patient Information Leaflets (PILs) are publicly available through government resources. These include national drug information databases like DailyMed and the National Institutes of Health (NIH) MedlinePlus Drug Information.

How should Clinovir be stored and disposed of?

How to Store and Dispose of Clinovir (Acyclovir)

Clinovir (Acyclovir) must be stored according to specific regulatory requirements to maintain its stability. The official labeling mandates storing the medication at Controlled Room Temperature, which is generally defined as 15 C to 25 C (59 F to 77 F). The product must be protected from both light and moisture and kept in a tight, light-resistant container.

Key Storage Constraints

Requirement	Specification
Temperature	Controlled Room Temperature.
Protection	Protected from light and moisture.
Child Safety	Keep out of the sight and reach of children.
Container	Must be tight and light-resistant.

For disposal, unused or expired Clinovir must be discarded in accordance with local regulatory requirements for pharmaceutical waste. Medicine should not be thrown away via wastewater or general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Indonesia

Thailand

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z